In lupus-prone mice, pDC depletion mitigates disease severity, and in humans, administration of an anti-BDCA2 antibody—selectively inhibiting pDC function—significantly attenuates the peripheral IFN-I signature [216,217,218]. This evidence concerns the gene PDC and systemic lupus erythematosus.